Zai Lab Ltd Closes $230 Million ADS Offering
Zai Lab (09688.HK) completed the issuance of American depositary shares and fully exercised the options.
On November 22, Glorious Holdings announced that Zai Lab (09688.HK) is pleased to announce that it will complete the public offering of a total of 7,843,137 American depositary shares at a price of $25.50 per American depositary share (equivalent to approximately HK$19.84 per share, calculated based on a ratio of 1 American depositary share for every 10 shares) on November 18, 2024 (Eastern Time, USA). In addition, the underwriters have fully exercised their options to purchase an additional 1,176,470 American depositary shares at the offering price minus the underwriting discount and commission.
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
Express News | Pfizer has reached a cooperation agreement with Zai Lab for a new antibacterial drug in mainland China.
Express News | Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug Xacduro® (Sulbactam-Durlobactam)
China ADRs Have Increased to the Largest Share Since Late 2021 – GS